Inactive Instrument

Analyst Reco. F-star Therapeutics, Inc.

Equities

HC Wainwright Downgrades F-star Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $35	22-07-15	MT
SVB Securities Downgrades F-star Therapeutics to Market Perform From Outperform; Price Target is $7	22-06-24	MT
Laidlaw Downgrades F-star Therapeutics to Hold From Buy	22-06-23	MT
Ladenburg Thalmann Downgrades F-star Therapeutics to Neutral From Buy	22-06-23	MT
William Blair Downgrades F-star Therapeutics to Market Perform From Outperform Rating	22-06-23	MT
SVB Securities Adjusts F-star Therapeutics' Price Target to $21 from $25, Keeps Outperform Rating	22-05-11	MT
Oppenheimer Adjusts F-star Therapeutics PT to $33 From $30, Maintains Outperform Rating	21-11-12	MT
F STAR THERAPEUTICS : SVB Leerink Adjusts Price Target on F-star Therapeutics to $35 From $39, Maintains Outperform Rating	21-08-17	MT
F STAR THERAPEUTICS : SVB Leerink Starts F-star Therapeutics at Outperform with $39 Price Target	21-07-08	MT
F STAR THERAPEUTICS : B. Riley Starts F-star Therapeutics at Buy with $28 Price Target	21-06-09	MT
F STAR THERAPEUTICS : Oppenheimer Initiates F-star Therapeutics at Outperform Rating With $30 Price Target	21-04-16	MT
F STAR THERAPEUTICS : William Blair Starts F-Star Therapeutics at Outperform	21-04-08	MT
F STAR THERAPEUTICS : HC Wainwright & Co. Initiates Coverage on F-star Therapeutics at Buy Rating, Sets Price Target at $35	21-03-01	MT

No results for this search